Logo
x

Search

Subscribe Now

Xolair

PharmaShots Interview: Genentech's Ted Omachi Shares Insight on the US FDA's Approval of Xolair in Nasal polyps

PharmaShots Interview: Genentech's Ted Omachi Shares Insight on the US FDA's Approval of Xolair in Nasal polyps

  • January 6, 2021
PharmaShots Interview: Genentech's Ted Omachi Shares Insights on Xolair (omalizumab) PFS

PharmaShots Interview: Genentech's Ted Omachi Shares Insights on Xolair (omalizumab) PFS

  • September 7, 2020
Roche Reports the US FDA's Acceptance of sBLA for Xolair (omalizumab) Prefilled Syringe for Self-Administration Across All Indications

Roche Reports the US FDA's Acceptance of sBLA for Xolair (omalizumab) Prefilled Syringe for Self-Administration Across All Indicat...

  • August 13, 2020
Insights+: Breakthrough Therapy Designation by the US FDA in 2018

Insights+: Breakthrough Therapy Designation by the US FDA in 2018

  • May 8, 2019
Celltrion’s CT-P39 (biosimilar, omalizumab) Receives the CHMP’s Recommendation for Marketing Authorization to Treat Multiple Indications

    Celltrion’s CT-P39 (biosimilar, omalizumab) Receives the CHMP’s Recommendation for Marketing Authorization to Treat Multiple Indic...

    • March 25, 2024
    Celltrion Submits BLA to the US FDA for CT-P39 (Biosimilar, Xolair)

      Celltrion Submits BLA to the US FDA for CT-P39 (Biosimilar, Xolair)

      • March 11, 2024
      Roche Reports the US FDA’s Approval of Xolair for Treating Food Allergies

        Roche Reports the US FDA’s Approval of Xolair for Treating Food Allergies

        • February 19, 2024
        Celltrion Reports Submission of a Marketing Application to Health Canada for CT-P39 for all Originator Indications

          Celltrion Reports Submission of a Marketing Application to Health Canada for CT-P39 for all Originator Indications

          • December 28, 2023
          Alvotech Entered into an Exclusive License Agreement with Kashiv BioSciences to Develop and Commercialize AVT23, a Proposed Biosimilar to Xolair (omalizumab)

            Alvotech Entered into an Exclusive License Agreement with Kashiv BioSciences to Develop and Commercialize AVT23, a Proposed Biosim...

            • October 4, 2023
            Alvotech Entered into Commercialization Agreement with Advanz Pharma for AVT23, a Proposed Biosimilar to Xolair (omalizumab)

              Alvotech Entered into Commercialization Agreement with Advanz Pharma for AVT23, a Proposed Biosimilar to Xolair (omalizumab)

              • February 6, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.